Chun Yu Liu

US Patent:

20220275007, Sep 1, 2022

Filed:

Jul 29, 2020

Appl. No.:

17/631741

Inventors:

- Durham NC, US
Yong-Kang ZHANG - San Jose CA, US
Chun Yu LIU - Durham NC, US
Marissa Caroline AUBREY - Durham NC, US

International Classification:

C07F 5/04
C07F 5/02
A01N 59/04

Abstract:

The present invention relates to methods of preparing benzoxaboroles. Benzoxaborole compounds have shown promise as antimicrobial agents, especially against fungal pathogens. The invention also relates to compositions of acyclic alkoxy boronic acid esters as intermediates, and continuous flow processes of mixing the intermediates with organomagnesium, magnesium, or organolithium reagents to form the desired benzoxaboroles.

US Patent:

20220242886, Aug 4, 2022

Filed:

Feb 1, 2022

Appl. No.:

17/590407

Inventors:

- Nashville TN, US
Chunliang LIU - Cary NC, US
Yong-Kang ZHANG - San Jose CA, US
Marissa AUBREY - Durham NC, US
Chun Yu LIU - Durham NC, US

International Classification:

C07F 5/02

Abstract:

The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

US Patent:

20210052614, Feb 25, 2021

Filed:

Nov 3, 2020

Appl. No.:

17/087962

Inventors:

- University Park PA, US
- Cold Spring Harbor NY, US
Chun Yu Liu - Cary NC, US
Chunliang Liu - Bellefonte PA, US

International Classification:

A61K 31/69
C07F 5/02

Abstract:

A method is disclosed for altering the redox equilibrium of a transmembrane receptor-like protein tyrosine phosphatase (RPTP), particularly a type IIa RPTP, by chemically modulating the activity through contact of such an enzyme with a diaryl boron compound that preferentially reacts with an RPTP in an oxidized state (CyS-OH). This redox modulation is most readily observed and put to use by assaying the inhibition of the phosphatase activity of the RPTP. Such an assay can be carried out on an enzyme in vitro or by contacting the enzyme in a living organism (in vivo). A useful diaryl boron compound corresponds in structure to Formula I in which Ar-1,Ar-2, R, R, Rand Rare defined within. A pharmaceutical composition containing a useful diaryl boron compound is also disclosed, as are particularly preferred diaryl boron compounds.

US Patent:

20200385409, Dec 10, 2020

Filed:

Nov 30, 2018

Appl. No.:

15/733157

Inventors:

- Durham NC, US
Chun Yu LIU - Durham NC, US
Chunliang LIU - Cary NC, US
Michael SAMUELS - Durham NC, US
Yong-Kang ZHANG - San Jose CA, US
Yasheen ZHOU - Moraga CA, US

International Classification:

C07F 5/02
A01N 55/08
A01N 25/04
A01N 25/08

Abstract:

A benzoxaborole formulation composition including a benzoxaborole, a non-ionic surfactant, or a non-ionic and ionic surfactant mixture, and a carrier is described herein. At least one of the non-ionic surfactant, the non-ionic and ionic surfactant mixture, and the carrier comprise a Lewis base or a N—H or O—H bond. The carrier is a solid or a liquid. Benzoxaborole compounds and methods of using the compounds and formulations of the compounds are described. For example, a method for reducing, preventing, ameliorating, or inhibiting an infestation by a pathogen by applying a compound or a formulation of a compound, wherein the pathogen is selected from insects, nematodes, bacteria, microbes, fungi, protozoa, viruses, and parasites, or any combinations thereof is described.

US Patent:

20180258106, Sep 13, 2018

Filed:

Mar 2, 2018

Appl. No.:

15/910677

Inventors:

- University Park PA, US
Nicholas K. Tonks - Huntington NY, US
Chun Yu Liu - Cary NC, US
Chunliang Liu - Bellefonte PA, US

International Classification:

C07F 5/02

Abstract:

A method is disclosed for altering the redox equilibrium of a transmembrane receptor-like protein tyrosine phosphatase (RPTP), particularly a type IIa RPTP, by chemically modulating the activity through contact of such an enzyme with a diaryl boron compound that preferentially reacts with an RPTP in an oxidized state (CyS-OH). This redox modulation is most readily observed and put to use by assaying the inhibition of the phosphatase activity of the RPTP. Such an assay can be carried out on an enzyme in vitro or by contacting the enzyme in a living organism (in vivo). A useful diaryl boron compound corresponds in structure to Formula I in which Ar-1,Ar-2, R, R, Rand Rare defined within. A pharmaceutical composition containing a useful diaryl boron compound is also disclosed, as are particularly preferred diaryl boron compounds.

US Patent:

20170345370, Nov 30, 2017

Filed:

May 31, 2016

Appl. No.:

15/169027

Inventors:

- Ewing NJ, US
Michael S. Weaver - Ewing NJ, US
Chun Hsin Liu - Ewing NJ, US

International Classification:

G09G 3/3258

Abstract:

A display according to various embodiments is disclosed. The display has a frontplane including at least one OLED pixel having multiple subpixels connected to at least one power line. A backplane of the display includes at least one driver circuit connected to two or more of the multiple subpixels. Methods for powering the display are also disclosed.